SCHEMBL7887374

SCHEMBL7887374

C=CCOC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)OCC)NC(=O)OCc1ccccc1)C1Cc2ccccc2C1)C(C)C

nearest known ligand 0.62

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 9/20 0.62
▸ CASP7 P55210 8/20 0.60
▸ CASP1 P29466 5/20 0.60
▸ CTSK P43235 3/20 0.46
▸ CTSB P07858 2/20 0.46
▸ CASP9 P55211 3/20 0.45
▸ CASP4 P49662 2/20 0.45
▸ CASP10 Q92851 2/20 0.45
▸ CASP8 Q14790 1/20 0.45
▸ CTSL P07711 1/20 0.41
▸ ELANE P08246 1/20 0.41
▸ REN P00797 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7882928 0.94 CASP3 (0.70) CASP3CASP7CASP1CTSKCTSB
SCHEMBL9962246 0.92 CASP3 (0.69) CASP3CASP7CASP1CTSKCTSB
SCHEMBL7887265 0.92 CASP3 (0.61) CASP3CASP7CASP1CTSKCTSB
SCHEMBL18471338 0.92 CASP3 (0.61) CASP3CASP7CASP1CTSKCTSB
SCHEMBL9961904 0.92 CASP3 (0.61) CASP3CASP7CASP1CTSKCTSB
SCHEMBL7889695 0.90 CASP3 (0.65) CASP3CASP7CASP1CTSKCTSB
SCHEMBL7887362 0.85 CASP3 (0.61) CASP3CASP7CASP1CTSKCTSB
SCHEMBL9962261 0.85 CASP3 (0.53) CASP3CASP7CASP1CTSKCTSB
SCHEMBL9962171 0.83 CASP3 (0.74) CASP3CASP7CASP1CTSKCTSB
SCHEMBL9961955 0.83 CASP3 (0.89) CASP3CASP7CASP1CASP9CASP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045524-B2 Selective caspase inhibitors and uses thereof NOVAGENESIS FOUNDATION (CH) 2015-06-02 — — US disclosed
WO-2010133000-A1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF NEW WORLD LABORATORIES INC. (CA) 2010-11-25 — — WO disclosed
Send feedback